Sight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients - SGHT News | RalliesSight Sciences TearCare wins FDA label expansion to improve meibomian gland function in dry eye patients
S
SGHT• FDA expands TearCare indication
- FDA updated the TearCare System indication effective Aug. 18, 2026 to include improving meibomian gland function in adult evaporative dry eye.
- The label now specifies use with manual meibomian gland expression; optional debridement was added as part of the cleared system.
- The change expands the product’s permitted marketing claims, potentially strengthening reimbursement and competitive positioning in MGD treatment.
MRK
•
